flucytosine has been researched along with Brain Neoplasms in 49 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Temozolomide (TMZ) with radiation is the most frequently used first-line treatment for patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults." | 7.79 | Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. ( Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M, 2013) |
| "Lomustine is a treatment option for patients with high-grade glioma." | 5.43 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016) |
| "5-Fluorouracil (5-FU) is a potent antimetabolite used for chemotherapy of gastrointestinal (GI), breast, and head and neck malignancies." | 5.31 | Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. ( Buchsbaum, DJ; Gillespie, GY; Miller, CR; Williams, CR, 2002) |
| " Temozolomide (TMZ) with radiation is the most frequently used first-line treatment for patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults." | 3.79 | Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. ( Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M, 2013) |
| "Since neural progenitor cells can engraft stably into brain tumors and differentiate along the neuronal and glial line, we tested the hypothesis that transplanted cytosine deaminase (CD)-expressing ST14A cells (an immortalized neural progenitor cell line) can convert locally 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and produce a regression of glioma tumors." | 3.72 | Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. ( Barresi, V; Belluardo, N; Cattaneo, E; Condorelli, DF; Mudò, G; Sipione, S, 2003) |
| "In this study, we investigated the feasibility of a double-suicide gene/prodrug therapy, involving direct introduction of the herpes simplex virus Type 1 thymidine kinase (TK) gene and the Escherichia coli cytosine deaminase (CD) gene, via a recombinant adenoviral vector, and ganciclovir (GCV) and/or 5-fluorocytosine (5-FC) treatment, in a rat C6 glioma model." | 3.70 | Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. ( Chang, JW; Chung, SS; Kim, E; Kim, JH; Lee, H; Lee, Y, 2000) |
| "Glioblastoma and anaplastic astrocytoma are two of the most aggressive and common glioma malignancies in adults." | 2.61 | Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. ( Adamson, DC; Philbrick, BD, 2019) |
| "Lomustine is a treatment option for patients with high-grade glioma." | 1.43 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016) |
| " Survival benefit is dose dependent for both vector and 5-FC, and as few as 4 cycles of 5-FC dosing after Toca 511 therapy provides significant survival advantage." | 1.38 | Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. ( Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT, 2012) |
| "The majority of brain metastases result from lung cancer, but the metastatic mechanism remains unclear." | 1.38 | Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties. ( Cho, MH; Choi, KC; Kim, SU; Kim, YB; Lee, HJ; Yi, BR, 2012) |
| "Immunohistochemistry of rat brain tumors inoculated with MSC-EGFP showed intratumoral distribution of MSC-EGFP." | 1.38 | Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. ( Date, I; Hamada, H; Ichikawa, T; Inoue, S; Kambara, H; Kosaka, H; Kurozumi, K; Maruo, T; Nakamura, K, 2012) |
| "In a novel experimental brain metastases model, intravenously administered F3 cells migrated near lung cancer metastatic lesions, which were induced by the injection of lung cancer cells via the intracarotid artery." | 1.38 | Neural stem cell-based dual suicide gene delivery for metastatic brain tumors. ( Ito, M; Iwami, K; Kim, SU; Kinjo, S; Lee, HJ; Momota, H; Motomura, K; Natsume, A; Nishimira, Y; Ohka, F; Ohno, M; Wakabayashi, T; Wang, C, 2012) |
| "In vivo, MDA-MB-435 human breast cancer cells were implanted into the brain of immune-deficient mouse stereotactically, and F3." | 1.35 | Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. ( Jin, J; Jo, MY; Joo, KM; Kang, BG; Kim, MH; Kim, SU; Lee, SJ; Nam, DH; Park, IH; Shin, JY, 2009) |
| "The infection of RG2 brain tumors with RCR-CD and their subsequent treatment with 5-FC significantly prolonged survival compared with that in animals with RG2 transduced tumors treated with PBS." | 1.33 | Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. ( Chen, TC; Kasahara, N; Kershaw, AD; Klatzmann, D; Solly, SK; Tai, CK; Wang, W, 2006) |
| "Rats bearing 9 L brain tumors were treated with an intratumoral injection of AdexCACD followed by intraperitoneal administration of 5-FC." | 1.31 | In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. ( Adachi, Y; Furuta, T; Hamada, H; Ichikawa, T; Matsumoto, K; Ohmoto, T; Ono, Y; Tamiya, T; Yoshida, Y, 2000) |
| " New interim measures of therapeutic response would be particularly useful in the development of cancer chemosensitization gene therapy by facilitating optimization of gene transfer protocols and prodrug dosing schedules." | 1.31 | Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. ( Chenevert, TL; Hamstra, DA; Jonas, SJ; Rehemtulla, A; Rice, DJ; Ross, BD; Stegman, LD; Stout, KL, 2000) |
| "5-Fluorouracil (5-FU) is a potent antimetabolite used for chemotherapy of gastrointestinal (GI), breast, and head and neck malignancies." | 1.31 | Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. ( Buchsbaum, DJ; Gillespie, GY; Miller, CR; Williams, CR, 2002) |
| " In vitro studies showed that 5-FC combined with CDase induced significant growth-inhibitory effects on the cultured glioma cells." | 1.27 | Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. ( Ito, T; Katsuragi, T; Kawamoto, K; Kawamura, Y; Matsumura, H; Nishiyama, T; Ohyama, A; Sakai, T; Yamamoto, N, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.08) | 18.7374 |
| 1990's | 5 (10.20) | 18.2507 |
| 2000's | 15 (30.61) | 29.6817 |
| 2010's | 24 (48.98) | 24.3611 |
| 2020's | 3 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SH | 1 |
| Sun, JM | 1 |
| Chen, BM | 1 |
| Lin, SC | 1 |
| Chang, HF | 1 |
| Collins, S | 1 |
| Chang, D | 1 |
| Wu, SF | 1 |
| Lu, YC | 1 |
| Wang, W | 2 |
| Chen, TC | 3 |
| Kasahara, N | 10 |
| Wang, HE | 1 |
| Tai, CK | 3 |
| Accomando, WP | 1 |
| Rao, AR | 2 |
| Hogan, DJ | 2 |
| Newman, AM | 1 |
| Nakao, A | 1 |
| Alizadeh, AA | 1 |
| Diehn, M | 1 |
| Diago, OR | 2 |
| Gammon, D | 2 |
| Haghighi, A | 1 |
| Gruber, HE | 8 |
| Jolly, DJ | 8 |
| Ostertag, D | 6 |
| Cloughesy, TF | 2 |
| Petrecca, K | 1 |
| Walbert, T | 2 |
| Butowski, N | 1 |
| Salacz, M | 1 |
| Perry, J | 1 |
| Damek, D | 1 |
| Bota, D | 1 |
| Bettegowda, C | 1 |
| Zhu, JJ | 1 |
| Iwamoto, F | 1 |
| Placantonakis, D | 1 |
| Kim, L | 1 |
| Elder, B | 1 |
| Kaptain, G | 1 |
| Cachia, D | 1 |
| Moshel, Y | 1 |
| Brem, S | 1 |
| Piccioni, D | 2 |
| Landolfi, J | 2 |
| Chen, CC | 2 |
| Gruber, H | 1 |
| Hogan, D | 1 |
| Accomando, W | 2 |
| Montellano, TT | 1 |
| Kheoh, T | 2 |
| Kabbinavar, F | 1 |
| Vogelbaum, MA | 2 |
| Mitchell, LA | 1 |
| Lopez Espinoza, F | 3 |
| Mendoza, D | 2 |
| Kato, Y | 2 |
| Inagaki, A | 2 |
| Hiraoka, K | 1 |
| Robbins, JM | 6 |
| Elder, JB | 1 |
| Bloomfield, S | 1 |
| Carter, B | 1 |
| Kalkanis, SN | 1 |
| Kesari, S | 1 |
| Lai, A | 1 |
| Lee, IY | 1 |
| Liau, LM | 1 |
| Mikkelsen, T | 1 |
| Nghiemphu, P | 1 |
| Das, A | 1 |
| Philbrick, BD | 1 |
| Adamson, DC | 1 |
| Kazlauskas, A | 1 |
| Darinskas, A | 1 |
| Meškys, R | 1 |
| Tamašauskas, A | 1 |
| Urbonavičius, J | 1 |
| Yin, D | 1 |
| Zhai, Y | 1 |
| Ibanez, CE | 5 |
| Kells, AP | 1 |
| Forsayeth, J | 1 |
| Bankiewicz, KS | 1 |
| Hickey, MJ | 1 |
| Malone, CC | 1 |
| Erickson, KL | 1 |
| Lin, A | 1 |
| Soto, H | 1 |
| Ha, ET | 1 |
| Kamijima, S | 1 |
| Takahashi, M | 1 |
| Mueller, BM | 1 |
| Kruse, CA | 1 |
| Kang, W | 1 |
| Seol, HJ | 1 |
| Seong, DH | 1 |
| Kim, J | 1 |
| Kim, Y | 2 |
| Kim, SU | 5 |
| Nam, DH | 3 |
| Joo, KM | 3 |
| Niu, J | 1 |
| Xing, C | 1 |
| Yan, C | 1 |
| Liu, H | 1 |
| Cui, Y | 1 |
| Peng, H | 1 |
| Chen, Y | 1 |
| Li, D | 1 |
| Jiang, C | 1 |
| Li, N | 1 |
| Yang, H | 2 |
| Parry, PV | 1 |
| Engh, JA | 1 |
| Huang, TT | 3 |
| Hlavaty, J | 3 |
| Espinoza, FL | 2 |
| Martin, B | 3 |
| Petznek, H | 2 |
| Rodriguez-Aguirre, M | 1 |
| Gunzburg, W | 2 |
| Pertschuk, D | 2 |
| Altaner, C | 2 |
| Altanerova, V | 2 |
| Cihova, M | 2 |
| Ondicova, K | 2 |
| Rychly, B | 2 |
| Baciak, L | 1 |
| Mravec, B | 2 |
| Parab, S | 1 |
| Burnett, R | 2 |
| Diago, O | 1 |
| Hofman, FM | 1 |
| Yagiz, K | 1 |
| Strebe, JK | 1 |
| Lubin, JA | 1 |
| Kuo, JS | 1 |
| Park, IH | 1 |
| Shin, JY | 1 |
| Jin, J | 2 |
| Kang, BG | 1 |
| Kim, MH | 1 |
| Lee, SJ | 2 |
| Jo, MY | 2 |
| Breton, E | 1 |
| Goetz, C | 1 |
| Kintz, J | 1 |
| Accart, N | 1 |
| Aubertin, G | 1 |
| Grellier, B | 1 |
| Erbs, P | 1 |
| Rooke, R | 1 |
| Constantinesco, A | 1 |
| Choquet, P | 1 |
| Chang, DY | 1 |
| Yoo, SW | 1 |
| Hong, Y | 1 |
| Kim, S | 1 |
| Kim, SJ | 1 |
| Yoon, SH | 1 |
| Cho, KG | 1 |
| Paek, SH | 1 |
| Lee, YD | 1 |
| Kim, SS | 1 |
| Suh-Kim, H | 1 |
| Jandl, G | 1 |
| Liszt, M | 1 |
| König-Schuster, M | 1 |
| Sedlak, J | 1 |
| Egerbacher, M | 1 |
| Weissenberger, J | 1 |
| Salmons, B | 1 |
| Günzburg, WH | 1 |
| Renner, M | 1 |
| Kim, HS | 1 |
| Jin, Y | 1 |
| Babic, M | 1 |
| Amundson, KK | 1 |
| Buckley, T | 1 |
| Galvão da Silva, AP | 1 |
| Lin, AH | 1 |
| Valenta, DT | 1 |
| Perez, OD | 1 |
| Chen, CI | 1 |
| Pettersson, PL | 1 |
| Daublebsky, V | 1 |
| Fei, S | 1 |
| Qi, X | 1 |
| Kedong, S | 1 |
| Guangchun, J | 1 |
| Jian, L | 1 |
| Wei, Q | 1 |
| Yi, BR | 1 |
| Kim, YB | 1 |
| Lee, HJ | 2 |
| Cho, MH | 1 |
| Choi, KC | 1 |
| Kosaka, H | 1 |
| Ichikawa, T | 3 |
| Kurozumi, K | 1 |
| Kambara, H | 1 |
| Inoue, S | 1 |
| Maruo, T | 1 |
| Nakamura, K | 1 |
| Hamada, H | 3 |
| Date, I | 1 |
| Wang, C | 1 |
| Natsume, A | 1 |
| Motomura, K | 1 |
| Nishimira, Y | 1 |
| Ohno, M | 1 |
| Ito, M | 1 |
| Kinjo, S | 1 |
| Momota, H | 1 |
| Iwami, K | 1 |
| Ohka, F | 1 |
| Wakabayashi, T | 1 |
| Barresi, V | 1 |
| Belluardo, N | 1 |
| Sipione, S | 1 |
| Mudò, G | 1 |
| Cattaneo, E | 1 |
| Condorelli, DF | 1 |
| Bourbeau, D | 1 |
| Lavoie, G | 1 |
| Nalbantoglu, J | 1 |
| Massie, B | 1 |
| Lü, SQ | 1 |
| Liu, YS | 1 |
| Wang, WJ | 1 |
| Kershaw, AD | 1 |
| Solly, SK | 1 |
| Klatzmann, D | 1 |
| Wei, J | 1 |
| Wahl, J | 1 |
| Knauss, H | 1 |
| Zeller, S | 1 |
| Jarmy, G | 1 |
| Fitze, G | 1 |
| Debatin, KM | 1 |
| Beltinger, C | 1 |
| Kaliberov, SA | 1 |
| Market, JM | 1 |
| Gillespie, GY | 2 |
| Krendelchtchikova, V | 1 |
| Della Manna, D | 1 |
| Sellers, JC | 1 |
| Kaliberova, LN | 1 |
| Black, ME | 1 |
| Buchsbaum, DJ | 2 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Vredenburgh, JJ | 1 |
| Friedman, AH | 1 |
| Sampson, JH | 1 |
| Nishiyama, T | 2 |
| Kawamura, Y | 2 |
| Kawamoto, K | 2 |
| Matsumura, H | 2 |
| Yamamoto, N | 2 |
| Ito, T | 2 |
| Ohyama, A | 2 |
| Katsuragi, T | 2 |
| Sakai, T | 2 |
| Ge, K | 2 |
| Xu, L | 1 |
| Zheng, Z | 1 |
| Xu, D | 1 |
| Sun, L | 1 |
| Liu, X | 1 |
| Xu, LF | 1 |
| Zheng, ZC | 1 |
| Sun, LY | 1 |
| Liu, XY | 1 |
| Liao, WC | 1 |
| Chang, WS | 1 |
| Wu, FY | 1 |
| Wang, ZH | 1 |
| Zagzag, D | 1 |
| Zeng, B | 1 |
| Kolodny, EH | 1 |
| Adachi, Y | 2 |
| Tamiya, T | 2 |
| Terada, K | 1 |
| Ono, Y | 2 |
| Matsumoto, K | 2 |
| Furuta, T | 2 |
| Ohmoto, T | 2 |
| Yoshida, Y | 1 |
| Stegman, LD | 1 |
| Rehemtulla, A | 1 |
| Hamstra, DA | 1 |
| Rice, DJ | 1 |
| Jonas, SJ | 1 |
| Stout, KL | 1 |
| Chenevert, TL | 1 |
| Ross, BD | 1 |
| Chang, JW | 1 |
| Lee, H | 1 |
| Kim, E | 1 |
| Lee, Y | 1 |
| Chung, SS | 1 |
| Kim, JH | 1 |
| Noble, M | 1 |
| Miller, CR | 1 |
| Williams, CR | 1 |
| Kchir, N | 1 |
| Bouratbine, A | 1 |
| Boubaker, S | 1 |
| Jemel, H | 1 |
| Haouet, S | 1 |
| Chatti, S | 1 |
| Khaldi, M | 1 |
| Zitouna, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor Decision) | ||
| Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade Astrocytomas[NCT05686798] | Phase 1 | 18 participants (Anticipated) | Interventional | 2022-11-29 | Recruiting | ||
| A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC[NCT01470794] | Phase 1 | 58 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma[NCT01156584] | Phase 1 | 54 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extende[NCT01985256] | Phase 1 | 17 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for flucytosine and Brain Neoplasms
| Article | Year |
|---|---|
Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cytosi | 2019 |
Can neural stem cells be used to track down and destroy migratory brain tumor cells while also providing a means of repairing tumor-associated damage?
Topics: Animals; Brain Neoplasms; Cell Movement; Combined Modality Therapy; Cytosine Deaminase; Flucytosine; | 2000 |
[Cerebral aspergillotic granuloma. Apropos of a case and a review of the literature].
Topics: Adult; Aged; Amphotericin B; Aspergillosis; Brain Diseases; Brain Neoplasms; Child; Diagnosis, Diffe | 1990 |
3 trials available for flucytosine and Brain Neoplasms
| Article | Year |
|---|---|
Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cyt | 2020 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Topics: Antimetabolites; Brain Neoplasms; Combined Modality Therapy; Cytosine Deaminase; Drug Synergism; Flu | 2018 |
43 other studies available for flucytosine and Brain Neoplasms
| Article | Year |
|---|---|
Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Topics: Animals; Aziridines; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Escherichia coli Protein | 2020 |
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Disease Model | 2017 |
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Caco-2 Cells; Cell Line, | 2019 |
Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model.
Topics: Animals; Brain Neoplasms; Convection; Cytosine Deaminase; Drug Delivery Systems; Flucytosine; Geneti | 2013 |
Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.
Topics: Adenoviridae; Animals; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cytosine Deamin | 2013 |
Adenosine potentiates the therapeutic effects of neural stem cells expressing cytosine deaminase against metastatic brain tumors.
Topics: Adenosine; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blood-Brain Barrier; Blotting, Weste | 2013 |
Lentivirus-mediated CD/TK fusion gene transfection neural stem cell therapy for C6 glioblastoma.
Topics: Animals; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosi | 2013 |
Neural stem cell-mediated enzyme/prodrug therapy for glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Glioma; Humans; Mi | 2013 |
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Dacarb | 2013 |
Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario.
Topics: Adipose Tissue; Animals; Antimetabolites; Bone Marrow; Brain Neoplasms; Cell Proliferation; Cells, C | 2014 |
Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Topics: Animals; Antibodies, Neutralizing; Antimetabolites; Brain Neoplasms; Clinical Trials as Topic; Cytos | 2015 |
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Diseas | 2016 |
"Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma.
Topics: Brain Neoplasms; Flucytosine; Glioblastoma; Glioma; Humans | 2016 |
Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Cell Line; Cell Proliferation; Cell Survival; Coculture | 2009 |
In vivo preclinical low-field MRI monitoring of tumor growth following a suicide-gene therapy in an orthotopic mice model of human glioblastoma.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Brain Neoplasms; Cytosine Deaminase; Fe | 2010 |
The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase.
Topics: Adolescent; Animals; Brain Neoplasms; Bystander Effect; Child; Chromatography, High Pressure Liquid; | 2010 |
Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.
Topics: Animals; Brain Neoplasms; Bystander Effect; Cytosine Deaminase; Disease Models, Animal; Drug Evaluat | 2011 |
Combined treatment of tumor-tropic human neural stem cells containing the CD suicide gene effectively targets brain tumors provoking a mild immune response.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Movement; Combined Modality Therapy; Cytosine | 2011 |
Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma.
Topics: Adipose Tissue; Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Cytosine Deam | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Genetic Ther | 2012 |
Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Topics: Animals; Brain Neoplasms; Cell Survival; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Engi | 2012 |
Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coculture Techniques; Cytosine Deaminase; | 2012 |
Neural stem cell-based dual suicide gene delivery for metastatic brain tumors.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Brain Neoplasms; Bystander Effect; Caro | 2012 |
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
Topics: Animals; Brain Neoplasms; Cells, Cultured; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluoro | 2003 |
Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status.
Topics: Adenoviridae; Antimetabolites; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Gene Expression Pro | 2004 |
[Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro].
Topics: Brain Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Th | 2004 |
Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.
Topics: Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Flucytosine; Genes, Transgenic, Suicide | 2005 |
Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA, Viral; Encep | 2006 |
Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Caspases; Cell Division; Cell Line, Tumor; Cloning, Molecular; | 2007 |
Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.
Topics: Adenoviridae; Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy | 2007 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
[Antineoplastic effect of 5-fluorocytosine and cytosine deaminase on brain tumor (author's transl)].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine; Cytosine Deaminase; Drug Therapy, Combina | 1982 |
Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Drug Resistance, Neop | 1997 |
[Experimental treatment of brain tumor cells using CD suicide gene].
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Escherichia coli; Flu | 1996 |
Re: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral | 1999 |
In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Cell Survival; Cyto | 1999 |
Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine.
Topics: Adenoviridae; Animals; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Gene Transfer Techniques; G | 2000 |
In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Brain; Brain Neoplasms; Cytosine Deaminase; | 2000 |
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.
Topics: Animals; Antifungal Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Genetic Therapy; Gliom | 2000 |
Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.
Topics: Adenoviridae; Animals; Antimetabolites; Antiviral Agents; Artificial Gene Fusion; Brain Neoplasms; C | 2000 |
Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Flucyto | 2002 |
Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.
Topics: Animals; Brain Neoplasms; Capsules; Cytosine; Cytosine Deaminase; Drug Evaluation, Preclinical; Drug | 1985 |